A political consensus seems to be emerging in the Senate Antitrust Subcommittee that negotiated settlements between the makers of brand-name drugs and generics to delay entry into the market are hurting...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: